nejm semaglutide heart failure New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://nej.md/4iYkLbj Oral and Cardiovascular Outcomes (SOUL trial) https://nej.md/4hHII5M Upadacitinib for Giant-Cell Arteritis Semaglutide and Cardiovascular Outcomes in
Description
Mahase E (2022) Type 1 diabetes drug was withdrawn because of a commercial conflict of interest, charity argues
Not all biomarkers changed, as AdaptAge, CausAge, and DamAge exhibited small, heterogeneous, non-significant shifts, and the Intrinsic Capacity (IC) clock, linked to physical and cognitive resilience, did not differ between groups (estimated group difference: 0.003 IC score
Regular monitoring by healthcare professionals helps track progress and make necessary adjustments.
Can weight-loss drugs make birth control pills less effective
This difference gives tirzepatide a unique mechanism of action
If you have Type 2 diabetes, obesity, or both, youve probably heard of the injectable medications that lower blood sugar and suppress appetite
